Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.30 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069743 | 0.79 | PDE2A (0.43) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL14364369 | 0.74 | AQP1 (0.42) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL9139591 | 0.70 | NISCH (0.52) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL30377758 | 0.70 | NISCH (0.52) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL10599581 | 0.68 | CYP2A6 (0.40) | NPC1RAB9ASMN1; SMN2HSD11B1TP53 | |
| SCHEMBL10094685 | 0.68 | ABL1 (0.46) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL10607765 | 0.68 | APP (0.47) | SMN1; SMN2 | |
| SCHEMBL18772851 | 0.67 | AGPAT2 (0.50) | NISCHPDE2APDE10AABL1AGPAT2 | |
| SCHEMBL7803538 | 0.67 | AHR (0.42) | RAB9AHSD11B1TP53CYP1A2 | |
| SCHEMBL600882 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | NISCH 4481/4885PDE2A 4581/4885PDE10A 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.